Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.Recruiting
NCT06697301Phase 2, Phase 3Updated May 8, 2026
Sponsor: Eikon Therapeutics
Advanced Melanoma
United States, Australia, Austria, Belgium, Canada +19 more
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)Terminated
NCT06295809Phase 2, Phase 3Updated May 8, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Squamous Cell · Skin Neoplasms
United States, Argentina, Australia, Belgium, Brazil +15 more
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy ParticipantsCompleted
NCT07279233Phase 1Updated May 8, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Healthy · Volunteer
United States
A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)Completed
NCT05558696Phase 2Updated May 7, 2026
Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Polycythemia Vera
United States, Australia, United Kingdom
DPX-Survivac and Checkpoint Inhibitor in DLBCLCompleted
NCT03349450Phase 2Updated May 6, 2026
Sponsor: Sunnybrook Health Sciences Centre
Adult Diffuse Large Cell Lymphoma · Recurrent · Adult Refractory Diffuse Large B-Cell Lymphoma
Canada
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)Recruiting
NCT06266338Phase 2Updated May 6, 2026
Sponsor: University of Texas Southwestern Medical Center
Cervix Cancer · Cervical Cancer
United States
A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)Completed
NCT07222098Phase 1Updated May 6, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial NeoplasiaCompleted
NCT03979014Phase 3Updated May 6, 2026
Sponsor: Imperial College London
Neoplasia
Finland, Sweden, United Kingdom
Targeting ATR in Soft-tissue SarcomasCompleted
NCT04807816Phase 2Updated May 5, 2026
Sponsor: Institut Bergonié
Leiomyosarcoma, Adult
France
Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine SurgeryCompleted
NCT05887375Phase 4Updated May 5, 2026
Sponsor: University of Missouri-Columbia
Spine Surgery · Reversal of Neuromuscular Blockade · Urinary Retention Postoperative
United States
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cmRecruiting
NCT04317534Phase 2Updated May 5, 2026
Sponsor: Greg Durm, MD
NSCLC, Stage I
United States
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)Active Not Recruiting
NCT05173987Phase 3Updated May 5, 2026
Sponsor: Merck Sharp & Dohme LLC
Endometrial Neoplasms
United States, Australia, Belgium, Brazil, Canada +22 more
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)Terminated
NCT04652700Phase 3Updated May 5, 2026
Sponsor: Merck Sharp & Dohme LLC
HIV Preexposure Prophylaxis
United States, Brazil, France, Japan, Peru +2 more
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.Active Not Recruiting
NCT05271318Phase 1, Phase 2Updated May 5, 2026
Sponsor: TILT Biotherapeutics Ltd.
Platinum-refractory Ovarian Carcinoma · Platinum-resistant Ovarian Cancer · Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma
United States, Finland
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)Completed
NCT04199104Phase 3Updated May 5, 2026
Sponsor: Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
United States, Australia, Brazil, Canada, China +14 more
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasRecruiting
NCT05956041Phase 2Updated May 5, 2026
Sponsor: University of Michigan Rogel Cancer Center
Cutaneous T Cell Lymphoma · Fungoides Mycosis Sezary Syndrome
United States
Cisplatin+Pembrolizumab+RT in Vulvar CancerActive Not Recruiting
NCT04430699Phase 2Updated May 5, 2026
Sponsor: Massachusetts General Hospital
Vulvar Cancer · Vulvar Squamous Cell Carcinoma
United States
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Active Not Recruiting
NCT04586231Phase 3Updated May 5, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
United States, Argentina, Australia, Austria, Belgium +20 more
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)Completed
NCT03797326Phase 2Updated May 4, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced Solid Tumors · Triple Negative Breast Cancer · Ovarian Cancer · Gastric Cancer
United States, Argentina, Australia, Canada, Chile +12 more
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)Terminated
NCT04663321Phase 2Updated May 4, 2026
Sponsor: Merck Sharp & Dohme LLC
Treatment Resistant Depression
United States
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid TumorsRecruiting
NCT06795412Phase 1, Phase 2Updated May 4, 2026
Sponsor: Pyxis Oncology, Inc
Advanced Solid Tumors
United States, France, Spain
Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)Completed
NCT04254978Phase 2Updated May 4, 2026
Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Essential Thrombocythemia
United States, Australia, Germany, Hong Kong, Italy +2 more
First in Human Study of M6223Completed
NCT04457778Phase 1Updated May 4, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Metastatic Solid Tumors
United States, Canada
Trial of Pembrolizumab in Cancer of Unknown PrimaryCompleted
NCT03752333Phase 2Updated May 4, 2026
Sponsor: Imperial College London
Cancer of Unknown Primary Site
United Kingdom
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell CarcinomaActive Not Recruiting
NCT02641093Phase 2Updated May 4, 2026
Sponsor: Trisha Wise-Draper
Head and Neck Cancer
United States

Previous page Next page